Safety, tolerability, and pharmacokinetics of single‐ and multiple‐ascending doses of olamkicept: Results from randomized, placebo‐controlled, first‐in‐human phase I trials

• मुख्य लेखकों: Frank‐Dietrich Wagner (लेखक), Stefan Schreiber (लेखक), Yu Bagger (लेखक), Katharina Bruzelius (लेखक), Ali Falahati (लेखक), Ola Sternebring (लेखक), Arjun Ravi (लेखक), Philippe Pinton (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Wiley, 2024-05-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Abstract Olamkicept selectively inhibits the cytokine interleukin‐6 (IL‐6) trans‐signaling pathway without blocking the classic pathway and is a promising immunoregulatory therapy for inflammatory bowel disease (IBD). These first‐in‐human, randomized, placebo‐controlled, single‐ (SAD) and multiple‐a...